---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-013762"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:15:27.478210+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports Q1 2023 cash of $37.3M, R&D expense up to $5.7M; Annamycin trial advances

## Summary
- Cash and equivalents of $37.3M as of March 31, 2023, expected to fund operations into Q3 2024.
- R&D expense increased to $5.7M from $4.6M YoY, primarily due to WPD sublicense termination.
- G&A expense increased to $2.6M from $2.4M YoY, driven by higher regulatory, legal, and consulting fees.
- Phase 1b/2 trial of Annamycin in AML (MB-106) completed first cohort; positive preclinical data presented at AACR 2023.

## SEC filing metadata
- accession: 0001437749-23-013762
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/0001437749-23-013762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/mbrx20230508c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-013762
- JSON: https://secwatch.observer/filing/0001437749-23-013762.json
- Plain text: https://secwatch.observer/filing/0001437749-23-013762.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and recent operational highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/0001437749-23-013762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.